Lifecore Biomedical
LFCR
92 hedge funds and large institutions have $235M invested in Lifecore Biomedical in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 16 closing their positions.
0.16% more ownership
Funds ownership: 86.53% → 86.68% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 95 → 92 (-3)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
17% less capital invested
Capital invested by funds: $285M → $235M (-$49.9M)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
89% less call options, than puts
Call options by funds: $11K | Put options by funds: $98K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
+$17.9M |
| 2 |
Morgan Stanley
New York
|
+$6.05M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$4.61M |
| 4 |
2L
22NW LP
Seattle,
Washington
|
+$3.3M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$929K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Walthausen & Co
Malta,
New York
|
-$4.36M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$2.42M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$2.33M |
| 4 |
SCM
SG Capital Management
Chicago,
Illinois
|
-$1.63M |
| 5 |
Bank of New York Mellon
New York
|
-$1.39M |
LFCR Hedge Fund Activity: Q3 2021 in Review
92 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2021, worth a combined $235M — down 17% from $285M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LFCR and 14 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 26 added.
The largest buyer was ISZO Capital Management, opening a new position worth an estimated $17.9M. The largest seller was Walthausen & Co, exiting entirely with an estimated $4.36M sold.
- 92 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2021, down from 95 in Q2 2021.
- Funds reported $235M of Lifecore Biomedical stock for Q3 2021, down 17% quarter-over-quarter.
- 14 funds opened new Lifecore Biomedical positions in Q3 2021 and 16 closed out, a net change of -2 holders.
- The largest Lifecore Biomedical buyer in Q3 2021 was ISZO Capital Management, an estimated $17.9M added.
- The largest Lifecore Biomedical seller in Q3 2021 was Walthausen & Co, an estimated $4.36M sold.
Based on aggregated 13F filings for Q3 2021.